Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
PML caused by John Cunningham (JC) virus is a rare but an increasingly recognized entity. With the advent of newer immunomodulatory therapies with monoclonal antibodies, there is an increasing incidence of PML. Initially concern was restricted to patients treated for multiple sclerosis with natalizu...
Saved in:
| Main Authors: | Michael A. Lane, Vijay Renga, Andrew R. Pachner, Jeffrey A. Cohen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Neurological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2015/892047 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Symptomatic Follicular Lymphoma: Complete Remission After Chemoimmunotherapy with Bendamustine–Rituximab
by: Wulyo Rajabto, et al.
Published: (2024-07-01) -
Bendamustine–rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS–STING activation in diffuse large B-cell lymphoma
by: Enguang Bi, et al.
Published: (2024-11-01) -
BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS.
by: Roberto Castelli
Published: (2016-07-01) -
Effectiveness of Bendamustine-Rituximab Compared to R-CHOP/R-CVP as a First-Line Treatment of Indolent Non-Hodgkin’s Lymphoma or Mantle-Cell Lymphoma
by: Brenda Cristie Edina, et al.
Published: (2022-07-01) -
Effect of Acalabrutinib in Combination with Bendamustine plus Rituximab on Survival Endpoints in Older Patients with Mantle Cell Lymphoma: Insights from the ECHO Trial
by: Adrian Schmidt
Published: (2024-12-01)